| Autor: |
Falcão MB; Research and Extension Center in Health Surveillance, State University of Feira de Santana, Feira de Santana, Brazil., Pamplona de Góes Cavalcanti L; Department of Community Health, School of Medicine, Federal University of Ceará, Fortaleza, Brazil., Filgueiras Filho NM; School of Medicine, Salvador University, Salvador, Brazil.; School of Medicine, State University of Bahia, Salvador, Brazil., Antunes de Brito CA; Department of Internal Medicine, Clinical Hospital of Federal University, Recife, Brazil.; Tropical Medicine post-graduation of Federal University of Pernambuco, Recife, Brazil.; Autoimmune Research Institute, Recife, Brazil. |
| Abstrakt: |
Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases. However, evidence of efficacy remains limited, and adverse events can be associated with its use. Here, we report a case of a patient with severe COVID-19 who, after being administered HCQ, exhibited a 10-fold increase in serum levels of transaminases, followed by a rapid decrease after HCQ was withdrawn. Considering the significantly increased use of HCQ during the COVID-19 pandemic, this case alerts us to the potential for HCQ to be associated with hepatotoxicity and the need to monitor liver function during HCQ therapy. |
